Study AP-ADF-106

This is a Phase I clinical study, for use in product labeling, evaluating the characteristics of crushed Acurox™ Tablets when snorted by 12-18 subjects with history of opioid abuse. We expect to initiate subject enrollment in this study in Q2-08.